Similar articles

• Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).

  Sader HS, Watters AA, Fritsche TR, Jones RN. Sader HS, et al. BMC Infect Dis. 2007 Apr 18;7:29. doi: 10.1186/1471-2334-7-29. BMC Infect Dis. 2007. PMID: 17442104 Free PMC article.
• In vitro activity of daptomycin against Staphylococcus aureus and vancomycin-resistant Enterococcus faecium isolates associated with skin and soft tissue infections: first results from India.

  Dhawan B, Gadepalli R, Kapil A. Dhawan B, et al. Diagn Microbiol Infect Dis. 2009 Oct;65(2):196-8. doi: 10.1016/j.diagmicrobio.2009.05.015. Diagn Microbiol Infect Dis. 2009. PMID: 19748433
• Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

  Sader HS, Jones RN. Sader HS, et al. Diagn Microbiol Infect Dis. 2009 Oct;65(2):158-62. doi: 10.1016/j.diagmicrobio.2009.06.016. Diagn Microbiol Infect Dis. 2009. PMID: 19748426
• In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.

  Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. Anastasiou DM, et al. Int J Antimicrob Agents. 2006 Nov;28(5):385-8. doi: 10.1016/j.ijantimicag.2006.07.017. Int J Antimicrob Agents. 2006. PMID: 17046205 Review.
• [Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)].

  Kuwahara K, Hanaki H, Hiramatsu K. Kuwahara K, et al. Ryoikibetsu Shokogun Shirizu. 1999;(23 Pt 1):182-5. Ryoikibetsu Shokogun Shirizu. 1999. PMID: 10088368 Review. Japanese. No abstract available.